Glenmede Trust Co. NA Cuts Stakes in Incyte and Williams‑Sonoma
Glenmede Trust Co. NA lowered its holding in Incyte Corporation during the first quarter, reducing its stake by 4.7% after selling 25,715 shares. The fund now owns about 0.26% of Incyte, valued at roughly $49.3 million.
In the same period, Glenmede also trimmed its position in Williams‑Sonoma, Inc., cutting its stake by 18.2% through the sale of 42,028 shares. Following the transaction, the trust holds approximately 0.16% of Williams‑Sonoma, worth about $34.4 million.
Entities: AbbVie · Apogee Therapeutics · Glenmede Trust Co. NA · Incyte Corporation · Skyrizi · Williams‑Sonoma, Inc.
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] After the sale, Glenmede owned about 0.16% of Williams‑Sonoma, valued at $34,443,000. (Glenmede Trust Co. NA)
- [○ 1 SOURCE] After the sale, Glenmede owned about 0.26% of Incyte, valued at $49,252,000. (Glenmede Trust Co. NA)
- [○ 1 SOURCE] Glenmede Trust Co. NA reduced its stake in Williams‑Sonoma by 18.2% during the first quarter, selling 42,028 shares. (Glenmede Trust Co. NA)
- [○ 1 SOURCE] Glenmede Trust Co. NA reduced its stake in Incyte by 4.7% during the first quarter, selling 25,715 shares. (Glenmede Trust Co. NA)